Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response Document date: 2020_4_14
ID: d7stppv5_110
Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint . Fig S7. Treatment projections of cytolytic immunotherapy assuming different potency and timing of treatment. Each set of simulations is performed under assumptions of high, medium and low potency based on multiplicative effect on infected cell death rate. Treatment initiation is at timepoints generally consistent with a. hospitalization (day 10 after first positive samp.....
Document: is the (which was not peer-reviewed) The copyright holder for this preprint . Fig S7. Treatment projections of cytolytic immunotherapy assuming different potency and timing of treatment. Each set of simulations is performed under assumptions of high, medium and low potency based on multiplicative effect on infected cell death rate. Treatment initiation is at timepoints generally consistent with a. hospitalization (day 10 after first positive sample), b. first symptoms (day 5 after first positive sample), c. pre-symptomatic post-peak phase (day 2 after first positive sample) and d. pre-symptomatic pre-peak phase (day 0). Overall, early potent treatment limits duration of infection.
Search related documents:
Co phrase search for related documents- cell death rate and infection duration: 1
- different potency and early potent treatment: 1
- different potency and infection duration: 1
- different potency and low medium high potency: 1
- different potency and positive sample: 1
- different potency and positive sample 10 day: 1
- different potency and positive sample 10 day hospitalization: 1
- different potency and post peak phase: 1
- different potency and pre peak phase: 1
- different potency and pre symptomatic pre peak phase: 1
- early potent treatment and infection duration: 1, 2, 3
- early potent treatment and low medium high potency: 1, 2
- early potent treatment and positive sample: 1, 2, 3
- early potent treatment and positive sample 10 day: 1, 2
- early potent treatment and positive sample 10 day hospitalization: 1, 2
- early potent treatment and post peak phase: 1, 2, 3
- early potent treatment and pre peak phase: 1, 2, 3
- early potent treatment and pre symptomatic pre peak phase: 1, 2
- infection duration and pre symptomatic pre peak phase: 1, 2
Co phrase search for related documents, hyperlinks ordered by date